The effect of royal jelly on the growth of breast cancer in mice

Zhang,Shuang; Shao,Qiqi; Geng,Haiyang; Su,Songkun

doi:10.3892/ol.2017.7078

The effect of royal jelly on the growth of breast cancer in mice

Authors:
- Shuang Zhang
- Qiqi Shao
- Haiyang Geng
- Songkun Su
View Affiliations

Affiliations: College of Bee Science, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China
Published online on: September 27, 2017 https://doi.org/10.3892/ol.2017.7078
Pages: 7615-7621

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to various pharmacological properties, including antioxidative, anti‑inflammatory and antibiotic properties, royal jelly (RJ) has been widely consumed in daily diets in numerous countries. In the present study, the effect of RJ on 4T1‑bearing mice was investigated. The study was performed by feeding 4T1‑bearing mice with RJ using either the prophylactic‑therapeutic (PTRJ) or therapeutic (TRJ) method. The experimental results for the PTRJ group demonstrated that the weight of tumor was significantly reduced (RJ 0.5 and 1.5 g/kg); and in the serum, the levels of interleukin (IL)‑2 (RJ 0.5 and 1.5 g/kg), interferon (IFN)‑α, superoxide dismutase (SOD) and total antioxidant capacity (T‑AOC) were significantly elevated, but the concentrations of IL‑4 (RJ 0.5 and 1.5 g/kg) and IL‑10 (RJ 1.0 g/kg) were significantly decreased. In addition, the activities of T‑AOC and glutathione reductase (GR) were significantly improved in the liver, whereas in the kidney, the activities of T‑AOC and GR were significantly increased only under the dose of 0.5 g/kg. For the TRJ group, the antitumor effect of RJ was not significant; the change in IL‑2, IFN‑α, SOD and T‑AOC levels in the serum, and the change in T‑AOC and GR in liver were similar to those observed in the PTRJ groups. RJ treatment was demonstrated to reduce the development of breast tumor in mice, and simultaneously improve the antioxidant capacity of the serum, liver and kidney, particularly using the prophylactic‑therapeutic method. These results corroborated the efficacy of RJ supplementation in diets. The results of the present study suggest that the antioxidant and immunomodulatory activities of RJ serve an important role on antitumor growth.

View Figures

View References

1	Isidorov V, Czyżewska U, Isidorova A and Bakier S: Gas chromatographic and mass spectrometric characterization of the organic acids extracted from some preparations containing lyophilized royal jelly. J Chromatogr B Analyt Technol Biomed Life Sci. 877:3776–3780. 2009. View Article : Google Scholar : PubMed/NCBI
2	Fujiwara S, Imai J, Fujiwara M, Yaeshima T, Kawashima T and Kobayashi K: A potent antibacterial protein in royal jelly. purification and determination of the primary structure of royalisin. J Biol Chem. 265:11333–11337. 1990.PubMed/NCBI
3	Karaca T, Uz YH, Demirtas S, Karaboga I and Can G: Protective effect of royal jelly in 2,4,6 trinitrobenzene sulfonic acid-induced colitis in rats. Iran J Basic Med Sci. 18:370–379. 2015.PubMed/NCBI
4	Arzi A, Olapour S, Yaghooti H and Karampour Sistani N: Effect of royal jelly on formalin induced-inflammation in rat hind paw. Jundishapur J Nat Pharm Prod. 10:e224662015. View Article : Google Scholar : PubMed/NCBI
5	Yildirim S, Karadeniz A, Karakoc A, Yildirim A, Kalkan Y and Şimşek N: Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin. Turk J Med Sci. 42:367–375. 2012.
6	Niu K, Guo H, Guo Y, Ebihara S, Asada M, Ohrui T, Furukawa K, Ichinose M, Yanai K, Kudo Y, et al: Royal jelly prevents the progression of sarcopenia in aged mice in vivo and in vitro. J Gerontol A Biol Sci Med Sci. 68:1482–1492. 2013. View Article : Google Scholar : PubMed/NCBI
7	Nomura M, Maruo N, Zamami Y, Takatori S, Doi S and Kawasaki H: Effect of long-term treatment with royal jelly on insulin resistance in otsuka long-evans tokushima fatty (OLETF) rats. Yakugaku Zasshi. 127:1877–1882. 2007. View Article : Google Scholar : PubMed/NCBI
8	Kashima Y, Kanematsu S, Asai S, Kusada M, Watanabe S, Kawashima T, Nakamura T, Shimada M, Goto T and Nagaoka S: Identification of a novel hypocholesterolemic protein, major royal jelly protein 1, derived from royal jelly. PLoS One. 9:e1050732014. View Article : Google Scholar : PubMed/NCBI
9	Nakaya M, Onda H, Sasaki K, Yukiyoshi A, Tachibana H and Yamada K: Effect of royal jelly on bisphenol A-induced proliferation of human breast cancer cells. Biosci Biotechnol Biochem. 71:253–255. 2007. View Article : Google Scholar : PubMed/NCBI
10	Salazar-Olivo L and Paz-González V: Screening of biological activities present in honeybee (Apis mellifera) royal jelly. Toxicol In Vitro. 19:645–651. 2005. View Article : Google Scholar : PubMed/NCBI
11	Oršolić N, Terzić S, Šver L and Bašić I: Honey-bee products in prevention and/or therapy of murine transplantable tumours. J Sci Food Agric. 85:363–370. 2005. View Article : Google Scholar
12	Šimúth J, Bíliková K, Kováčová E, Kuzmová Z and Schroder W: Immunochemical approach to detection of ddulteration in honey: Physiologically active royal jelly protein stimulating TNF-alpha release is a regular component of honey. J Agric Food Chem. 52:2154–2158. 2004. View Article : Google Scholar : PubMed/NCBI
13	Mishima S, Suzuki KM, Isohama Y, Kuratsu N, Araki Y, Inoue M and Miyata T: Royal jelly has estrogenic effects in vitro and in vivo. J Ethnopharmacol. 101:215–220. 2005. View Article : Google Scholar : PubMed/NCBI
14	Suzuki KM, Isohama Y, Maruyama H, Yamada Y, Narita Y, Ohta S, Araki Y, Miyata T and Mishima S: Estrogenic activities of fatty acids and a sterol isolated from royal jelly. Evid Based Complement Alternat Med. 5:295–302. 2008. View Article : Google Scholar : PubMed/NCBI
15	Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP and Sherman ME: Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 13:1558–1568. 2004.PubMed/NCBI
16	Samavat H and Kurzer MS: Estrogen metabolism and breast cancer. Cancer Lett. 356:231–243. 2015. View Article : Google Scholar : PubMed/NCBI
17	Iwase H: Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. Int J Clin Oncol. 20:249–252. 2015. View Article : Google Scholar : PubMed/NCBI
18	Taavoni S, Barkhordari F, Goushegir A and Haghani H: Effect of Royal Jelly on premenstrual syndrome among Iranian medical sciences students: A randomized, triple-blind, placebo-controlled study. Complement Ther Med. 22:601–606. 2014. View Article : Google Scholar : PubMed/NCBI
19	Pulaski BA and Ostrand-Rosenberg S: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res. 58:1486–1493. 1998.PubMed/NCBI
20	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
21	Luo KW, Ko CH, Yue GG, Lee JK, Li KK, Lee M, Li G, Fung KP, Leung PC and Lau CB: Green tea (Camellia sinensis) extract inhibits both the metastasis and osteolytic components of mammary cancer 4T1 lesions in mice. J Nutr Biochem. 25:395–403. 2014. View Article : Google Scholar : PubMed/NCBI
22	Bincoletto C, Eberlin S, Figueiredo CA, Luengo MB and Queiroz ML: Effects produced by royal jelly on haematopoiesis: Relation with host resistance against ehrlich ascites tumour challenge. Int Immunopharmacol. 5:679–688. 2005. View Article : Google Scholar : PubMed/NCBI
23	Tamura T, Fujii A and Kuboyama N: Antitumor effects of royal jelly (RJ). Nihon Yakurigaku Zasshi. 89:73–80. 1987.(In Japanese). View Article : Google Scholar : PubMed/NCBI
24	Shirzad M, Kordyazdi R, Shahinfard N and Nikokar M: Does royal jelly affect tumor cells ? J HerbMed Pharmacol. 2:45–48. 2013.
25	Townsend GF, Morgan JF and Hazlett B: Activity of 10-hydroxydecenoic acid from royal jelly against experimental leukaemia and ascitic tumours. Nature. 183:1270–1271. 1959. View Article : Google Scholar : PubMed/NCBI
26	Townsend GF, Morgan JF, Tolnai S, Hazlett B, Morton HJ and Shuel RW: Studies on the in vitro antitumor activity of fatty acids I. 10-hydroxy-2-decenoic acid from royal jelly. Cancer Res. 20:503–510. 1960.PubMed/NCBI
27	Male D: Reactions against blood cells and plateletsInL Immunology. 4th Edition. Roitt I, Brostoff J and Male D: Mosby; London: pp. 3–23. 1996
28	Liu RM, Zhang XJ, Liang GY, Yang YF, Zhong JJ and Xiao JH: Antitumor and antimetastatic activities of chloroform extract of medicinal mushroom cordyceps taii in mouse models. BMC Complement Altern Med. 15:2162015. View Article : Google Scholar : PubMed/NCBI
29	Murugaiyan G and Saha B: IL-27 in tumor immunity and immunotherapy. Trends Mol Med. 19:108–116. 2013. View Article : Google Scholar : PubMed/NCBI
30	Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, et al: Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 72:5188–5197. 2012. View Article : Google Scholar : PubMed/NCBI
31	Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, et al: Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells. Int J Cancer. 133:771–778. 2013. View Article : Google Scholar : PubMed/NCBI
32	Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, Bondanza A, Gentner B, De Palma M, Mazzieri R and Naldini L: Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression. Sci Transl Med. 6:217ra32014. View Article : Google Scholar : PubMed/NCBI
33	Gasic S, Vucevic D, Vasilijic S, Antunovic M, Chinou I and Colic M: Evaluation of the immunomodulatory activities of royal jelly components in vitro. Immunopharmacol Immunotoxicol. 29:521–536. 2007. View Article : Google Scholar : PubMed/NCBI
34	Okamoto I, Taniguchi Y, Kunikata T, Kohno K, Iwaki K, Ikeda M and Kurimoto M: Major royal jelly protein 3 modulates immune responses in vitro and in vivo. Life Sci. 73:2029–2045. 2003. View Article : Google Scholar : PubMed/NCBI
35	Oka H, Emori Y, Kobayashi N, Hayashi Y and Nomoto K: Suppression of allergic reactions by royal jelly in association with the restoration of macrophage function and the improvement of Th1/Th2 cell responses. Int Immunopharmacol. 1:521–532. 2001. View Article : Google Scholar : PubMed/NCBI
36	Erem C, Deger O, Ovali E and Barlak Y: The effects of royal jelly on autoimmunity in Graves' disease. Endocrine. 30:175–183. 2006. View Article : Google Scholar : PubMed/NCBI
37	Cebrian A, Pharoah PD, Ahmed S, Smith PL, Luccarini C, Luben R, Redman K, Munday H, Easton DF, Dunning AM and Ponder BA: Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res. 66:1225–1233. 2006. View Article : Google Scholar : PubMed/NCBI
38	Şener DE, Gönenç A, Akıncı M and Torun M: Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct. 25:377–382. 2007. View Article : Google Scholar : PubMed/NCBI
39	Samy RP, Gopalakrishnakone P and Ignacimuthu S: Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Chem Biol Interact. 164:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
40	Karadeniz A, Simsek N, Karakus E, Yildirim S, Kara A, Can I, Kisa F, Emre H and Turkeli M: Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin. Oxid Med Cell Longev. 2011:9817932011. View Article : Google Scholar : PubMed/NCBI
41	Jamnik P, Goranovič D and Raspor P: Antioxidative action of royal jelly in the yeast cell. Exp Gerontol. 42:594–600. 2007. View Article : Google Scholar : PubMed/NCBI
42	Gómez-Caravaca AM, Gómez-Romero M, Arráez-Román D, Segura-Carretero A and Fernández-Gutiérrez A: Advances in the analysis of phenolic compounds in products derived from bees. J Pharm Biomed Anal. 41:1220–1234. 2006. View Article : Google Scholar : PubMed/NCBI
43	Da Silva RJ, Da Silva MG, Vilela LC and Fecchio D: Cytokine profile of ehrlich ascites tumor treated with Bothrops jararaca venom. Mediators Inflamm. 11:197–201. 2002. View Article : Google Scholar : PubMed/NCBI